Nausheen Ahmed

24PUBLICATIONS
154CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursHaematologyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Apr 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen, Danai Dima, Hira Mian

|Nov 21, 2025
Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

Manisha Bhutani, Alma Habib, Andrew Vegel

|Jul 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.

Nausheen Ahmed, Swetha Kambhampati Thiruvengadam, Mehdi Hamadani

|Jul 07, 2025
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.

Miguel-Angel Perales, Farrukh T Awan, Ariane Boumendil

|May 05, 2025
Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines.

Aqeeb Ur Rehman, Fathima Shehnaz Ayoobkhan, Moazzam Shahzad

|Apr 08, 2025
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.

Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar

Pageof 4

Frequent Collaborators

10 joint publications

Joseph P McGurik

6 joint publications

Mehdi Hamadani

4 joint publications

James A Davis

4 joint publications

Mohamed A Kharfan-Dabaja